Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (470)	7/10/2003 8:55:30 PM
From: SemiBull	Read Replies (1) \| Respond to of 668

CURIS INC (CRIS) - form 8-K Item 5. Other Events and Required FD Disclosure. Curis, Inc., a Delaware corporation (“Curis”), is filing this current report on Form 8-K for the purpose of filing with the Securities and Exchange Commission (“SEC”) its press release dated June 11, 2003 announcing that it has licensed its small molecule and antibody inhibitors of the Hedgehog signaling pathway to Genentech, Inc. (“Genentech”) for applications in cancer therapy pursuant to the terms of a Collaborative Research, Development and License Agreement dated June 11, 2003 (the “Collaboration Agreement”). In partial consideration for the rights and licenses granted by Curis under the Collaboration Agreement, Curis sold to Genentech 1,323,835 shares (the “Shares”) of its common stock at a purchase price of $2.644 per share, pursuant to the terms of a Stock Purchase Agreement dated June 11, 2003 (the “Stock Purchase Agreement”). The Company entered into a Registration Rights Agreement with Genentech on June 13, 2003 (the “Registration Rights Agreement”) covering the registration of the Shares for resale under specified conditions. Copies of the Collaboration Agreement, Stock Purchase Agreement, Registration Rights Agreement and press release have been filed as Exhibits 10.1, 10.2, 10.3, and 99.1, respectively, to this Current Report on Form 8-K. Item 7. Financial Statements and Exhibits. (c) Exhibits Exhibit No. Description ----------- --------------------------------------------------------------------- +10.1 Collaborative Research, Development and License Agreement, dated as of June 11, 2003 between Company and Genentech. 10.2 Common Stock Purchase Agreement, dated June 11, 2003, between the Company and Genentech. 10.3 Registration Rights Agreement, dated June 13, 2003, between the Company and Genentech. 99.1 Press Release, dated June 11, 2003. + Confidential treatment requested as to certain portions of this exhibit, which portions have been separately filed with the Securities and Exchange Commission.